In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m 2 fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median follow-up of 1123 days (range, 47-2729 days), 20 patients (40%) are alive and free from disease. The probabilities of 1-, 2-and 3-year survival were 57, 47 and 39%, respectively. Patients who achieved a remission before HSCT had a significantly better OS compared with those who had active disease (P ¼ 0.01). The incidences of grade II-IV and III-IV acute GvHD (aGvHD) were 54% (n ¼ 27) and 16% (n ¼ 8). Remarkably, using tacrolimus and MMF, the median onset of aGvHD occurred distinctly late on day þ 66 (range, 12-119 days). A total of 46 patients were evaluable for chronic GvHD (cGvHD). Out of these, 26 (56%) patients developed cGvHD, with 16 (34%) of them showing limited and 10 (21%) showing extensive disease. We conclude that the combination of tacrolimus and MMF as post transplant immunosuppression for patients receiving NM unrelated donor HSCT permits stable engraftment and effective prophylaxis for acute and cGvHD. In particular, the occurrence of severe early-onset aGvHD was attenuated.
Introduction
Allogeneic hematopoietic SCT has increasingly emerged as a therapeutic option for hematological malignancies due to the development of nonmyeloablative (NM) conditioning regimens, 1 the growing number of donors available from international registries 2 and the improved results of unrelated donor transplantations. 3, 4 The last one is a consequence of accomplishments made in donor matching and the prophylaxis and treatment of GvHD and its related complications. 4, 5 However, long-term results of unrelated donor transplantations following NM conditioning are still overshadowed by a relatively high incidence of non-relapse mortality caused by acute GvHD (aGvHD), with or without infectious complications. 6 As regimen-related toxicities have already been reduced by using the lowest possible dosages, further attempts to reduce treatment-related toxicity have to optimize the modalities of GvHD prophylaxis. This effort is hampered by the fact that tumor eradication following NM conditioning relies almost exclusively on the immune-mediated graft-vstumor effect. Therefore, a treatment that simply reduces the incidence of GvHD is almost inherently counterbalanced by higher rates of relapse mortality. 7, 8 This dilemma is most significant in patients with previous treatment failure or refractory disease, and becomes more important due to an increased usage of NM allo-transplants as final salvage strategy for patients with advanced or active disease. [9] [10] [11] [12] [13] [14] Traditionally, a combination of CsA and mycophenolate mofetil (MMF) has been used as GvHD prophylaxis in the context of fludarabine/2 Gy TBI allografting, a NM regimen developed by Storb and colleagues in Seattle. 15, 16, 17 In 2005, Nieto et al. 18 observed low rates of early-onset aGvHD in 32 patients receiving matched-sibling transplants, after conditioning with fludarabine/TBI using a combination of tacrolimus and MMF as GvHD prophylaxis. Tacrolimus was introduced in the late 1980s as an alternative to CsA for the prevention of graft rejection following solid organ transplantation. Similar to CsA, tacrolimus functions by inhibition of the phosphorylase activity of calcineurin, resulting in the downregulation of interleukin-2 gene expression. 19, 20 According to this background, we performed a prospective clinical trial using tacrolimus and MMF as GvHD prophylaxis in a group of 50 patients with advanced hematological malignancies. Following the Seattle regimen (fludarabine/2 Gy TBI) for truly NM conditioning, all patients received unrelated grafts.
Patients and methods

Patients
All patients gave written informed consent and were treated prospectively within two consecutive protocols approved by the local Ethics Committee of the Heinrich Heine University Duesseldorf. Between May 2001 and August 2009, a total of 50 patients (male n ¼ 36, female n ¼ 14) were enrolled (Table 1) .
Median patient age at the time of transplantation was 51 years (range 25-67 years). All the 50 patients received transplants (PBSC n ¼ 47, BM n ¼ 3) from unrelated donors. With regard to HLA phenotype, 43 patients had an identical donor matched at HLA-A, -B, -C, -Dq and -Dr alleles using high-resolution DNA typing, whereas six patients had a donor with a single-allele mismatch (two HLA-C, two HLA-Dqb1, two HLA-A) and one patient had a donor with a mismatch in two alleles (HLA-B and HLA-C). The median number of CD34 þ cells within the allografts was 7.1 Â 10 6 /kg bodyweight (BW) (range 2.9 Â 10 6 -23.5 Â 10 6 per kg BW). Patient diagnosis was as follows: 22 patients had nonHodgkin's lymphoma (seven follicular, five mantle cell, four diffuse large cell, six T-cell), one had Hodgkin's disease, three had multiple myeloma ( two IgG kappa, one asecretory) and one had renal cell carcinoma. A total of 13 patients suffered from acute myeloid leukemia (three M1, four M2, one M3, one M5a, one M6, three secondary acute myeloid leukemia (SAML)), six from myelodysplastic syndrome (one refractory anemia, two refractory cytopenia with multilineage dysplasia, two refractory anemia with excess blasts, one chronic myelomonocytic leukemia) and four from chronic myeloid leukemia (one chronic phase, three in acceleration phase). The great majority of patients had received extensive previous cytotoxic therapies. A total of 10 patients (20%) had previous radiotherapy and 29 patients (58%) had undergone high-dose chemotherapy with autologous blood stem cell support. Overall, a median of seven previous chemotherapy cycles (range 0-17) and a median of three previous chemotherapy regimens (range 0-7) were administered before NM allogeneic SCT. All patients were ineligible for myeloablative SCT. The reasons were age 455 years (n ¼ 23), comorbidity associated with reduced organ function (n ¼ 20) or previous high-dose chemotherapy with autotransplant (n ¼ 29). At the time of allogeneic transplantation 28 patients (56%) had active disease (25 refractory to chemotherapy, 3 untreated), whereas 22 patients (44%) were in CR (four CR1, five CR2, seven4CR2) or PR (six4PR1). In October 2009, the median follow-up time for the patients alive was 1123 days (range 47-2729 days) ( Table 2) .
Transplantation procedure, immunosuppression, supportive care and chimerism All patients underwent the same preparative regimen that included low-dose TBI (2 Gy on day 0) and fludarabine (30 mg/m 2 on days À4, À3 and À2). Following TBI, granulocyte-colony stimulating factor-mobilized PBSCs (n ¼ 47) or BM (n ¼ 3) was infused. Immunosuppression was started on day -1 with tacrolimus (0.06 mg/kg p.o.) twice daily. One h after HSCT, oral MMF (Cellcept 3 Â 1 g or Myfortic 3 Â 720 mg) was added. Patients with BW less than 60 kg received 3 Â 750 mg Cellcept or an equivalent dose of Myfortic. Measurements of tacrolimus baseline concentrations in the blood were performed at least twice a week. For the first 70 days, the median tacrolimus baseline concentration of all patients was 9.7 ng/mL (range 8.4 (week 9)-12.6 (week 4) ng/mL). The dose was reduced in case of serum creatinine elevations of more than 1.5 times baseline concentration. In case of blood concentrations 420 ng/mL, the administration was discontinued followed by 25% holding-dose reduction. In addition, blood pressure, renal function and electrolyte levels were assessed twice a week in all patients receiving full-dose tacrolimus. In the absence of GvHD, MMF administration was tapered beginning on day þ 28 till day þ 50. Dose adjustments of MMF for gastrointestinal toxicity required 25% dose reduction, with a further 25% reduction in case of no improvement. Persistent MMF-related toxicity demanded discontinuation without tapering. Tacrolimus administration was individualized depending on the underlying disease activity and appearance of GvHD. In patients with relapse or disease progression tacrolimus was tapered before day þ 70. Patients without progressive diseases (PDs) received tacrolimus as scheduled. In this study dose reduction was started on day þ 70. All patients received Tacrolimus and MMF following matched unrelated nonmyeloablative-SCT F Zohren et al prophylactic ciprofloxacin and metronidazol for selective intestinal decontamination, from the beginning of conditioning therapy until hematological reconstitution. Furthermore, prophylactic fluconazole 200 mg/day was administered from the day of stem-cell infusion until discontinuation of immunosuppression. Antiviral prophylaxis was applied to all patients using either famciclovir 250 mg twice daily or, based on the CMV serologic status, ganciclovir 5 mg per kg BW once a day. Trimethoprimsulphamethoxazole was used as prophylaxis against Pneumocystis jiroveci and given until reconstitution of T4-Helper lymphocyte 4200 cells/mL after HSCT. Quantitative chimerism analyses were performed using short-tandem repeat-based PCR (STR-PCR) techniques at regular intervals of every 4 weeks following allografting from whole-blood samples and on days þ 28, þ 100 and þ 365 from BM.
GvHD grading and treatment
Diagnosis and clinical grading of acute and chronic GvHD (cGvHD) were performed according to established criteria. 21, 22 Initial treatment of aGvHD consisted of methylprednisolone (1-2 mg per kg BW per day; taper started after 14 days) and the administration of tacrolimus was resumed at full dosage. MMF was resumed to full dose only in case of aGvHD not involving the intestinal tract, within the first 50 days after HSCT. Steroid-refractory aGvHD was treated with additional T-cell and tumor necrosis factor-a-directed monoclonal antibodies, such as basiliximab and infliximab.
Donor lymphocyte infusion
In patients who suffered from PD after HSCT, immunosuppressive therapy was instantly reduced. Patients with PD without GvHD symptoms after discontinuation of immunosuppressive therapy received donor lymphocyte infusion (DLI) beginning with 1 Â 10 6 T-cells per kg BW. If disease progression persisted, a second DLI of 5 Â 10 6 T-cells per kg BW was infused. Patients suffering from 4grade 2 GvHD after DLI did not receive any further DLI.
Statistical methods EFS, GvHD-onset and OS were calculated from the day of transplantation to the respective event. Death from any cause was counted as an event in case of OS; both death and relapse were counted as events for the estimation of EFS. All time-to-event curves were estimated according to the Kaplan-Meier method. Differences between groups were calculated by the log-rank test. To identify risk factors for the development of acute or cGvHD, the following variables were examined by univariate and multivariate analysis using a multiple regression model: age, disease subtype, remission status at transplant, PB chimerism, donor/recipient sex, HLA mismatch, CMV reactivation and GvHD status. All statistical analyses were performed using SPSS statistical software.
Results
Regimen-related toxicity, engraftment and chimerism
In general, the conditioning regimen was well tolerated. Extrahematological toxicity was mild and limited to mild gastrointestinal symptoms. For instance, there were 12% of the patients presenting grade II-III nausea or vomiting and 5% showing grade II-III mucositis. Hematological toxicity varied between patients and was not attributable to the underlying disease status or the type or amount of previous cytotoxic therapy. The According to this definition 48 patients successfully engrafted (96%), whereas two patients (4%) experienced primary graft failure (Table 2) . One was observed in a patient with refractory acute myeloid leukemia, who had received BM (4.2 Â 10 6 CD34 þ per kg BW) from an unrelated donor with HLA-B and HLA-C mismatch. In this patient, a rescue using PBSC from the same donor (6.4 Â 10 6 CD34 þ per kg BW) also failed. The patient underwent further chemotherapy, but died after 722 days due to PD. The second graft failure was observed in a patient with renal cell carcinoma who had received 8.7 Â 10 6 CD34 þ per kg BW PBSC. This patient was put on sorafenib and is currently alive in stable disease at day þ 1484.
Both the median percentages of donor chimerism among PB and BM samples and the chimerism status of patients are shown in Table 3 . A complete donor chimerism was observed in 85% of the evaluable patients 12 months after HSCT, whereas 15% had a mixed chimerism with a proportion between 30 and 99% of donor origin. It is worth noting that 41 of 50 patients (82%) achieved a complete donor chimerism at any time after HSCT, irrespective of the underlying disease. Patients with lymphoid malignancies achieved a significantly higher degree of donor chimerism within the first month after HSCT compared with patients with myeloid malignancies (data not shown, Po0.05). Within the latter group of patients disease progression was associated with a decline of donor chimerism attributable to the disappearance of transplanted allogeneic hematopoietic cells as a consequence of the expanding malignant cells. In contrast, all patients with lymphoid malignancies who developed relapse or PD after transplantation maintained a complete donor chimerism.
Acute GvHD
All patients received allografts from unrelated donors. A total of 43 donors were matched for 10 Ags, 6 donors Tacrolimus and MMF following matched unrelated nonmyeloablative-SCT F Zohren et al for 9 and 1 donor for 8 Ags. Five male and 8 female patients had female donors ( Table 2) . A total of 28 patients (56%) developed aGvHD, excluding 4 patients who developed GvHD symptoms after DLI. 27 patients (54%) had grade II-IV, whereas grade III-IV aGvHD developed in 8 patients (16%) (Figure 1) . By univariate analysis, risk factors for the development of aGvHD were a PB donor chimerism of 495% within 28 days after PBSCT (P ¼ 0.002) and a sex-mismatched donor (P ¼ 0.138). It is interesting that HLA disparity had no effect on the incidence of aGvHD in our patients.
A total of 24 patients (48%) had classic aGvHD, whereas 4 patients (8%; unique patient number (UPN) 29, 43, 47 and 54) had late-onset aGvHD on days þ 104, þ 113, þ 119 and þ 111. In all patients first symptoms were noted at a median time of 66 days (range 12-119 days) after transplantation. Independent of the grade of aGvHD, organs involved were skin (n ¼ 25), gut (n ¼ 14) and liver (n ¼ 12).
Thirteen of the 32 patients with aGvHD (including GvHD after DLI) are currently alive and free of disease. In 5 patients (UPN 6, 11, 20, 21 and 41) the aGvHD symptoms resolved, whereas 23 patients developed cGvHD. As a consequence, 19 of 32 patients with aGvHD symptoms died: 7 due to disease progression and 12 due to non-relapse mortality (Table 2 and Figure 1 ).
Chronic GvHD
A total of 46 patients were evaluable for cGvHD. Out of these, 28 patients (61%) developed cGvHD (18 limited, 40%, 10 extensive, 21%) (Figure 2 ). Five patients (UPN 25, 26, 27, 37 and 39) showed de novo cGvHD (four limited, one extensive) on days þ 138, þ 159, þ 134, þ 138 and þ 360, whereas 23 patients (50%) had suffered from previous episodes of aGVHD. Among these, 21 (45%) had an overlap syndrome of acute and cGvHD symptoms, whereas 2 patients (UPN 32 and 47) presented classic cGvHD after complete clearance of aGvHD symptoms on days þ 159 and þ 181. GvHD symptoms occurred spontaneously in 21 patients (45%), whereas 7 patients experienced onset of GvHD after disease progression (UPN 2 and 19 after DLI; UPN 29, 37, 40, 51 and 55 after taper or rapid discontinuation of immunosuppressive therapy). Involvement of skin was observed in 23 patients, of liver in 9 patients and of gut in 10 patients. 
Survival, outcome and status of underlying disease
The group of patients included in this study was heterogeneous with regard to diagnosis, disease status before transplantation and type of previous therapy. At a median follow-up time of 1123 days (range 47-2729 days), 20 patients (40%) were alive ( Table 2 and Figure 3a) . The probabilities of 1-, 2-and 3-year survival were 57, 47 and 39%, respectively (Figure 3a) . Patients who achieved a CR or PR before HSCT had a significantly better OS compared with patients who had active or refractory disease (P ¼ 0.01). The Kaplan-Meier probabilities of 1-, 2-and 3-year OS for patients in remission were 73, 64 and 59%, and those for patients with refractory or active disease at the time of transplantation were 47, 34 and 20% (Figure 3b ). The recipients of high-dose chemotherapy and autologous blood SCT before NM HSCT had a trend towards shorter OS compared with patients who had not received dose-escalated chemotherapy (51, 38 and 33% vs 67, 55 and 49%, P ¼ 0.11). The age of patients did not affect the OS in this group.
A total of 16 patients (32%) died from relapse or refractory disease following a median time of 211 days (range 69-747 days) after transplantation. It is worth noting that 11 out of these 16 patients developed neither acute nor cGvHD, whereas two had aGvHD grade II-III and three others showed aGVHD and cGvHD. This analysis includes patient UPN 2 and 17, who developed GvHD only after DLI.
13 patients (26%) died from treatment-related complications after a median time of 307 days (range 31-1457 days). Of these patients, one (UPN 23) died from aGvHD grade III-IV causing multi-organ failure on day þ 121. The majority of 9 patients (UPN: 8, 9, 10, 12, 13, 24, 26, 32 and 39) died from infectious complications, mainly as a result of escalated GvHD treatment. Nevertheless, there were also 3 patients (UPN 6, 20 and 11) who died due to infectious complications without underlying GvHD on day þ 185, þ 261 and þ 474 after transplantation. The lethal infections included overwhelming Gram-negative septicemia (n ¼ 6), aspergillus pneumonia (n ¼ 3), CMV encephalitis (n ¼ 1), VZV encephalitis (n ¼ 1) and meningoencephalitis caused by an unidentified microorganism (n ¼ 1) (Figure 4) .
One patient, UPN 19, committed suicide in CR around day þ 1432.
Toxicity
Nephrotoxicity was the most common non-hematological side effect observed within the first 100 days after transplantation. To assess renal failure, patients were evaluated for baseline serum creatinine concentrations at showed normal creatinine levels throughout the whole post transplantation period, there was no need to discontinue tacrolimus therapy for toxicity in any patient. It is worth noting that all patients required supplementation of magnesium during full-dose tacrolimus therapy. Neurological side effects, such as mild nausea, vomiting and headache, were only seen during the first 2 weeks after transplantation. Six patients developed a transient mild tremor, which was exclusively seen when tacrolimus serum concentrations were 415 ng/mL. In our study, we observed no case of severe mucositis, venous occlusive disease or transplant-associated thrombotic microangiopathy.
Discussion
Although regimen-related toxicities and acute transplantation-associated morbidity considerably decreased following the introduction of NM preparative regimen, aGvHD remains the major cause of treatment-related mortality. 6, 23 Therefore, improved prevention of aGvHD, especially in patients receiving matched unrelated grafts, could be a feasible strategy to further enhance the long-term results of this treatment. As a translation of canine preclinical studies, a combination of CsA and MMF is widely used for the prophylaxis of GvHD and graft rejection in NM allo-HSCT. 15, 16 A different approach uses the combination of tacrolimus and MMF, which showed excellent early post transplant survival, while facilitating effective control of acute and cGvHD in NM-matched sibling HSCT. 18 Moreover, a combination of tacrolimus and MTX was tested in three randomized clinical trials, showing a significantly lower incidence of aGvHD as compared with the combination of CsA and MTX in both matched related and unrelated transplantations. [24] [25] [26] In this report, we show for the first time in the context of NM conditioning that tacrolimus in combination with MMF is an efficient and well-tolerated GvHD prophylaxis in patients receiving an unrelated donor graft. The only side effect, which was attributable to tacrolimus, was nephrotoxicity. Despite the relatively advanced age of our patients, with a median of 51 years, renal insufficiency caused by tacrolimus was reversible and none of the patients needed hemodialysis during treatment. Nevertheless, it cannot be ruled out that several other factors might also have contributed to renal injury, such as GvHD, subclinical transplantation-associated thrombotic microangiopathy or capillary leak sydrome. In line with other reports, the rate of severe cytopenias was very low and lifethreatening infections within the first 150 days after transplantation were only seen in patients suffering from severe GvHD, necessitating escalated immunosuppressive therapy. Considering the lack of secondary graft rejection and the low rate of primary graft failure, we conclude that the combination of tacrolimus and MMF permits reliable hematological engraftment in the majority of patients. It is interesting that all patients who gradually lost donor hematopoiesis after successful initial engraftment suffered from PD.
The overall frequencies of grade 2-4 aGvHD and cGvHD obtained in our study compare well with previously reported incidences in adult NM HLA-matched unrelated donor transplantations using CsA and MMF. In these studies, aGvHD was observed in 52, 17 63 15 and 74%, 27 whereas cGvHD occurred in 37, 17 30 15 and 67% 27 of the patients. In our study, 54% of the patients developed aGvHD grade II-IV after a median time of 66 days following transplantation. With regard to cGvHD, results from our trial (cGvHD 56%; extensive 21% and limited 34%) and published data using CsA and MMF for NMmatched unrelated donor HSCT are also similar, 15, 17, 27, 28 indicating the efficacy of tacrolimus and MMF in the prevention of GvHD. Despite the similar incidences of acute and cGvHD, we found that the onset of aGvHD in our patients, receiving tacrolimus and MMF, was markedly later (day þ 66), when compared with the above-mentioned trials (day þ 30) using CsA and MMF in NM-unrelated donor HSCT. Considering the influence of PB donor chimerism on aGvHD onset observed in this study, it is worth mentioning that there was no delay in the achievement of a complete donor chimerism in our patients compared with patients receiving CsA and MMF, which could account for the observed delay in aGvHD onset. However, our finding is in line with the report of Nieto et al., 18 who observed the onset of aGvHD after a median time of 71 days post transplantation using tacrolimus and MMF following NM-matched sibling HSCT, which per se is associated with a lower rate of severe GvHD. On the basis of these findings, we conclude that the combination of tacrolimus and MMF might be superior to CsA and MMF as far as the prevention of early-onset aGvHD is concerned. Moreover, the combination of tacrolimus and MMF prevented aGvHD in 5 out of 7 patients with HLAmismatched grafts. As reported by the Seattle group, Tacrolimus and MMF following matched unrelated nonmyeloablative-SCT F Zohren et al aGvHD is associated with increased TRM, but not with improved disease control, for which cGvHD seems to be more important. 6, 29 This indicates that the observed effect of a late aGvHD onset could translate into a better general outcome, a hypothesis that is strengthened by the work of Mielcarek et al., who found that patients after NM HSCT from related donors with late onset of aGvHD had a favorable outcome in comparison with those suffering from early onset of aGvHD. 29 In that respect we observed only two treatment-related deaths within the first 150 days after HSCT, which were both attributable to aGvHD (UPN 31 and 10). This overall low rate of TRM within the first 150 days reflects the safety and efficacy of tacrolimus in combination with MMF following NM-matched unrelated donor transplantation.
Although the results of our study suggest the possibility to reduce TRM by intensification of aGvHD prophylaxis using tacrolimus and MMF, there are some aspects that need to be discussed in more detail. First, in our study we administered tacrolimus in full dose until day þ 70 with gradual taper through day þ 100, which could explain why we observed severe late-onset aGvHD in four patients between day þ 104 and þ 119. In the same line, four of the five patients who developed de novo cGvHD were diagnosed between day þ 134 and þ 159, indicating a high risk for GvHD development in the early period after withdrawal of immunosuppression. We therefore envisage administering tacrolimus for a longer period, for instance through day þ 180, as it is done with CsA by many investigators. 15, 29, 30 This could help to further reduce the incidence of acute and cGvHD, and would be particularly suitable for patients in CR.
On the other hand, in patients at great risk for relapse, a GVL effect is wanted to eradicate residual malignant cells. This relevance of a GVL effect might be, at least partially, reflected by the finding that 9 out of 16 patients who died due to PD developed neither acute nor cGvHD symptoms. In line with the results published by Baron et al., 6 19 out of 32 patients with aGvHD died, 7 from PD and 12 due to TRM, indicating a higher incidence of non-relapse mortality among patients suffering from aGvHD. Contrary to this study, we also observed a high incidence of TRM among patients with extensive cGvHD within a median follow-up of 500 days (range 177-1457 days). In our study, 6 out of 10 patients suffering from extensive cGvHD died due to TRM on day þ 252, þ 304, þ 616, þ 787, þ 1336 and þ 1457 after transplantation. Therefore, it is reasonable to assume that patients suffering from extensive cGVHD are at risk to die from TRM even years after transplantation. Longer follow-up periods are crucially needed to confirm whether extensive cGvHD is not associated with increased non-relapse mortality. On the other hand, 13 out of 18 patients treated within our study who had limited cGvHD are currently alive and free from disease at a median follow-up of 1224 days after transplantation.
Although there is evidence that patients with active disease at the time of NM HSCT can achieve a PR or CR in up to 57%, 6 their probability of achieving long-lasting remissions is very small. [10] [11] [12] [13] 31, 32 The long-term results observed in our patients who failed to achieve remission before NM conditioning are poor, with a corresponding 3-year OS probability of 20%, which is significantly lower than the 59% for patients treated in remission.
In summary, the combination of tacrolimus and MMF for immunosuppression in older patients receiving matched unrelated NM HSCT was well tolerated, permits stable engraftment and was not associated with specific early or long-term related toxicities. Our data suggest that this GvHD prophylaxis is associated with a lower risk of earlyonset aGvHD in comparison with the combination of CsA and MMF. We therefore propose that the tacrolimus and MMF prophylaxis should be evaluated prospectively in randomized trials.
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